In March 2024, a preclinical study titled “Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models” was published in Molecular Cancer Therapeutics. This study demonstrated that Raludotatug Deruxtecan, developed by Daiichi Sankyo, is effective against human ovarian and kidney cancer models. Additionally, […]
At the 2024 ASCO Annual Meeting, one of the highlights was the MRG004A-001 study conducted by Professor Yu Xianjun’s team, marking a milestone in the exploration of escalating doses of MRG004A, an ADC drug targeting tissue factor TF/CD142. Carried out in the United States and China, the study’s findings are significant. Among 12 evaluated pancreatic […]
At the 2024 ASCO Annual Meeting, HANGZHOU DAC BIOTECHNOLOGY (abbreviated as DAC Biotech) presented preclinical data on their STEAP1 ADC, DXC008. This ADC targets both STEAP1 and PSMA, showing high affinity for STEAP1 and moderate affinity for PSMA. Preclinical data demonstrated that a single dose of 1 mpk produced durable anti-tumor responses in xenograft models […]
During the 2024 ASCO conference, Professor Zhang Jian of Fudan University’s Cancer Hospital unveiled the Phase I/II clinical trial outcomes for 9MW2821, an ADC drug targeting Nectin-4, designed to combat advanced solid tumors. The drug demonstrated promising results, particularly in treating urothelial carcinoma, cervical cancer, esophageal cancer, and triple-negative breast cancer. Concurrently, CSPS showcased their […]
The 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024) will take place in Chicago, USA, from May 31st to June 4th. As a major event in the cancer treatment community, it will reveal many important clinical research outcomes and the latest innovations. Antibody-drug conjugates (ADCs), which cleverly combine targeted antibody therapies with powerful […]
Folate receptor alpha (FRα), due to its differential expression in various tumor or cancer tissues compared to normal tissues, is considered an ideal druggable target. In the past, pharmaceutical companies have ventured into developing FRα-targeted therapies, including small molecule conjugates and monoclonal antibody drugs like Morphotek’s humanized monoclonal antibody farletuzumab, and Endocyte’s small molecule conjugate […]
In December 2023, GlaxoSmithKline (“GSK”) invested $1.71 billion to obtain the global exclusive rights for the development, production, and commercialization of HS-20093 from HANSON PHARAM (excluding mainland China, Hong Kong, Macau, and Taiwan). HS-20093 is a novel B7-H3 targeted antibody-drug conjugate (ADC) developed independently by HANSON PHARAM. Similarly, in April 2024, Macrogenics’ stock price surged […]
Antibody-drug conjugates (ADCs) have been one of the hottest areas in the biopharmaceutical industry in recent years. Pharmaceutical giants such as Pfizer, AbbVie, AstraZeneca, and Merck are investing billions of dollars in breakthrough technologies targeting cancer treatment. According to the latest report from the market intelligence company Evaluate, in 2023, the total value of ADC-focused […]
In March 2022, a study published in Nature Cancer highlighted Cadherin 17 (CDH17) as an ideal target for chimeric antigen receptor (CAR) T-cell therapy in gastrointestinal tumors (including gastric cancer, pancreatic cancer, and colorectal cancer) and neuroendocrine tumors (NETs). CDH17 swiftly gained attention across major news platforms, providing fresh insights into tumor-associated antigens and the […]
Since Ganymed unveiled the efficacy data of Zolbetuximab (IMAB362), the anti-Claudin18.2 monoclonal antibody, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJ) at the 2016 ASCO conference, Claudin18.2 has emerged as a focal point for pharmaceutical companies eager to advance therapeutic options. These companies explore various technological routes, including monoclonal antibodies, bispecific antibodies, […]